论文部分内容阅读
五种新抗菌剂为日本大正制药公司研制的“TE-031”、日本三共公司研制的“CS-807”、法国Rucel Ukulafu公司研制的“RU28965”、日本北陆制药公司研制的“NY-198”、日本大鹏药品公司及Hekisto日本分公司研制的“THR-221”。“TE-031”以红霉素为原料合成,主要抗肺炎球菌、流感嗜血杆菌,甚至对短杆菌、支原体(青霉素类和头孢菌素类对它们作用弱)也具有很强的抗菌活力,该品可作口服剂使用。1985年11月起,在日本一千多个医疗单位试用。在1836个病例中,1821例确认有效,有效率为77%。对各种疾病的临床疗
Five new antibacterial agents are “TE-031” manufactured by Japan’s Taisho Pharmaceutical Co., Ltd., “CS-807” manufactured by Japan’s Sankyo Co., Ltd., “RU28965” manufactured by France’s Rucel Ukulafu Co., Ltd., “NY- 198 ”, Japan Dapeng drug companies and Hekisto Japan branch developed the“ THR-221. ” “TE-031” is synthesized from erythromycin, which is mainly anti-pneumococcus and Haemophilus influenzae, and even has strong antibacterial activity against Brevibacterium, Mycoplasma (penicillins and cephalosporins are weak to them) The product can be used as oral agent. Since November 1985, more than 1,000 medical units in Japan have been trialled. Among 1836 cases, 1821 cases were confirmed to be effective with an effective rate of 77%. Clinical treatment of various diseases